4D Molecular Therapeutics, Inc. (FDMT) stock
FDMTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/300% above fair value
$12.12−0.88 (-6.74%)
Close on Nov 12, 2026Market cap $874.46MP/E –Yield –
4D Molecular Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
4D Molecular Therapeutics's price to sales ratio was 7.8× on Nov 11, 2026, against 24.7× a year earlier. Over the last 3 years it ranged from 5.9× to 396.8×, with a median of 31.4×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 7.8× | −25.7 |
| 2024 | Jan 31, 2024 | 33.5× | −5.9 |
| 2023 | Dec 29, 2023 | 39.4× | −325.2 |
| 2022 | Dec 30, 2022 | 364.6× | +333.2 |
| 2021 | Jan 29, 2021 | 31.4× | +0.7 |
| 2020 | Dec 31, 2020 | 30.7× | – |
See a number that looks wrong?